B40.89 Other forms of blastomycosis

Name of the Condition

• Other forms of blastomycosis

Summary

Other forms of blastomycosis represent fungal infections caused by Blastomyces dermatitidis (and related species) that affect body sites beyond the lungs, skin, bones, or central nervous system. These infections result from hematogenous spread of the fungus from a primary pulmonary site or, rarely, direct inoculation. Clinical manifestations vary by affected organ but typically involve localized symptoms related to the involved tissue. The condition is part of the broader blastomycosis spectrum and requires targeted evaluation based on the specific site of infection.

Causes

The infection arises from the dissemination of Blastomyces yeast, which originates from a primary pulmonary infection. Inhalation of airborne spores from soil or decaying organic matter in endemic regions initiates the disease. Once in the lungs, spores convert to yeast, multiply, and may enter the bloodstream to spread to other organs. Direct inoculation through skin wounds is uncommon but possible in certain exposures.

Risk Factors

• Residence in or travel to endemic areas (e.g., parts of North America, particularly the Ohio and Mississippi River valleys).
• Immunocompromised states (e.g., HIV/AIDS, organ transplantation, chronic steroid use).
• Occupational or recreational exposure to soil (e.g., construction, forestry, gardening).
• Advanced age.
• Untreated or disseminated blastomycosis at other sites.

Symptoms

• Site-specific symptoms depending on the affected organ (e.g., genitourinary, gastrointestinal, or other rare sites).
• Systemic signs such as fever, fatigue, or weight loss may occur with disseminated disease.
• Localized pain, swelling, or functional impairment related to the involved tissue.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, exposure history, and targeted testing. Laboratory confirmation may include culture, histopathology, or antigen detection from affected tissues. Imaging (e.g., CT, MRI) helps identify organ involvement. Serologic tests are less reliable for non-pulmonary or non-cutaneous sites. Biopsy of the affected tissue often provides definitive evidence of fungal elements.

Treatment Options

Antifungal therapy is the mainstay, typically with amphotericin B (initially) followed by itraconazole for mild to moderate cases. Treatment duration varies by site and severity, often lasting 6–12 months. Severe or disseminated infections may require prolonged or combination therapy. Adjunctive measures address complications (e.g., drainage of abscesses).

Prognosis and Follow-Up

Prognosis depends on the site of infection, immune status, and timeliness of treatment. Early intervention improves outcomes, but delays can lead to irreversible damage. Follow-up includes monitoring for treatment response, recurrence, or complications. Immunocompromised patients may need extended therapy and closer surveillance.

Complications

• Organ-specific damage (e.g., renal impairment, gastrointestinal perforation) from untreated infection.
• Dissemination to other sites if not adequately treated.
• Treatment-related adverse effects (e.g., nephrotoxicity from amphotericin B).

Lifestyle & Prevention

• Avoid disturbing soil in endemic areas, especially during activities like gardening or construction.
• Wear protective gear (e.g., masks) when exposure to dust or decaying matter is likely.
• Promptly treat underlying immunocompromising conditions to reduce risk of severe disease.
• Seek early medical evaluation for persistent symptoms after potential exposure.

When to Seek Professional Help

Consult a healthcare provider for unexplained symptoms (e.g., localized pain, fever, or organ-specific issues) after exposure to endemic regions or soil. Seek immediate care for severe symptoms (e.g., high fever, difficulty breathing, or neurological changes), as these may indicate disseminated disease.

Tips for Medical Coders

Code B40.89 is assigned for blastomycosis affecting sites not classified elsewhere (e.g., genitourinary, gastrointestinal). Document the specific affected organ or system to support coding accuracy. Ensure clinical correlation with exposure history, test results, or biopsy findings. Avoid using this code for pulmonary, cutaneous, osseous, or central nervous system blastomycosis, which have dedicated codes.